Francisco Luján-Méndez

Dr. Francisco Luján-Méndez

Faculty of Chemistry, Autonomous University of Queretaro, Querétaro City, Mexico
orcid
"From lab bench to bedside"

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2023 in Cells
Verified
Journal Article
Open access
PDF file
Francisco Luján-MéndezFrancisco Luján-Méndez
Francisco Luján-Méndez
OPOctavio Roldán Padrón
Octavio Roldán Padrón
JRJesús Eduardo Castro Ruiz
Jesús Eduardo Castro Ruiz
JLJosué López-Martínez
Josué López-Martínez
Teresa García-GascaTeresa García-Gasca
Teresa García-Gasca
Capsaicinoids are a unique chemical species resulting from a particular biosynthesis pathway of hot chilies (Capsicum spp.) that gives rise to 22 analogous compounds, all of which are TRPV1 agonists and, therefore, responsible for the pungency of Capsicum fruits. In addition to their human consumption, numerous ethnopharmacological uses of chili have emerged throughout history. Today, more than 25 years of basic research accredit a multifaceted bioactivity mainly to capsaicin, highlighting its antitumor properties mediated by cytotoxicity and immunological adjuvancy against at least 74 varieties of cancer, while non-cancer cells tend to have greater tolerance. However, despite the progress regarding the understanding of its mechanisms of action, the benefit and safety of capsaicinoids’ pharmacological use remain subjects of discussion, since capsaicin also promotes epithelial–mesenchymal transition, in an ambivalence that has been referred to as “the double-edge sword”. Here, we update the comparative discussion of relevant reports about capsaicinoids’ bioactivity in a plethora of experimental models of cancer in terms of selectivity, efficacy, and safety. Through an integration of the underlying mechanisms, as well as inherent aspects of cancer biology, we propose mechanistic models regarding the dichotomy of their effects. Finally, we discuss a selection of in vivo evidence concerning capsaicinoids’ immunomodulatory properties against cancer.

13 September 2023
Verified
Book Chapter
Closed access
BGBertha Isabel Carvajal Gamez
Bertha Isabel Carvajal Gamez
TGTeresa García Gasca
Teresa García Gasca
ARAndrea Margarita Olvera Ramírez
Andrea Margarita Olvera Ramírez
ABAída Olguín Barrera
Aída Olguín Barrera
JSJorge Chávez Servín
Jorge Chávez Servín
JMJuan Mosqueda
Juan Mosqueda

5 February 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Francisco Luján-MéndezFrancisco Luján-Méndez
Francisco Luján-Méndez
PGPatricia Garcia-Lopez
Patricia Garcia-Lopez
Laura C BerumenLaura C Berumen
Laura C Berumen
GGGUADALUPE GARCIA-ALCOCER
GUADALUPE GARCIA-ALCOCER
Roberto Augusto Ferriz-MartínezRoberto Augusto Ferriz-Martínez
Roberto Augusto Ferriz-Martínez
Teresa García-GascaTeresa García-Gasca
Teresa García-Gasca
Background: rTBL-1, a recombinant lectin from Phaseolus acutifolius, exhibit proapoptotic activity on colon cancer cells and inhibitory properties on colon tumorigenesis in vivo. Apoptosis has been associated with a phospho-EGFR/phospho-p38/phospho-p53 mechanistic axis. Immunogenicity data have been observed in treated animals, but its possible involvement in the antitumor response remained unexplored. Objective: We investigated whether the cytotoxic activity of rTBL-1 depends on EGFR and its capacity to produce antitumor responses on syngeneic colon cancer in mice, with and without T cells, in order to explore its possible involvement in the process. Results:rTBL-1 exhibited cytotoxic effects in a concentration-dependent manner in both EGFR+ (MC-38) and EGFR− (CT-26) colon cancer cells with LC50 values of 23.50 and 30.01 µg/mL, respectively (p = 0.063). Apoptotic effects were slower and longer-lasting in MC-38 than in CT-26 cells. Significant increases in caspase-3 proteolytic activation and PARP1 cleavage were detected in both cell types, despite PARP1 rheostasis in CT-26 cells. Intralesional treatment with rTBL-1 inhibited the growth of established tumors in immunocompetent BALB/c mice in 27.81% (p = 0.0008) with a benefit in survival (p = 0.022), but not in immunodeficient BALB/c nude mice. Conclusions:rTBL-1 induces apoptosis in colon cancer cells by EGFR independent mechanisms, although its presence could be related to deeper responses. Unresponsiveness in nude mice indicated that rTBL-1 antitumor effect is the synergistic result of apoptosis induction and T cell-mediated cytotoxicity in the tumor. Future studies will focus on the immunogenic effects triggered by the antitumor activity of rTBL-1 in colon cancer.

29 April 2016
Verified
Other
Closed access
Francisco Luján-MéndezFrancisco Luján-Méndez
Francisco Luján-Méndez
DMDaniel Alejandro Arriaga Madrid
Daniel Alejandro Arriaga Madrid
RSRodríguez-Sánchez S
Rodríguez-Sánchez S
YRYolanda Rodríguez-Aza
Yolanda Rodríguez-Aza
RVRosalía Virginia Ocampo Velázquez
Rosalía Virginia Ocampo Velázquez
LFLuján-Méndez F
Luján-Méndez F

22 September 2023
Verified
Report
Closed access
Francisco Luján-MéndezFrancisco Luján-Méndez
Francisco Luján-Méndez
ACAnette Aylín Ramírez Carrera
Anette Aylín Ramírez Carrera
JBJaqueline González Barrón
Jaqueline González Barrón
FMFrancisco Campos Maldonado
Francisco Campos Maldonado
RRRicardo Fosado Rodríguez
Ricardo Fosado Rodríguez
TGTeresa Garcia Gasca
Teresa Garcia Gasca